Human Recombinant ERBB3 protein, ECD, hFc Tag (V2LY-0526-LY4531)

Name: Human Recombinant ERBB3 protein, ECD, hFc Tag
SKU: V2LY-0526-LY4531
Rating: 5 (1 reviews)

See all ERBB3 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Expressed Host

HEK293 Cells

Protein Species

Human

Tag

hFc Tag

Protein Construction

This product is Human Recombinant ERBB3 protein, ECD, hFc Tag consist of Amino Acid: 1-643 and predicts a molecular mass of 95.4 kDa.

Molecule Mass

95.4 kDa

Protein Domain

ECD

Verified

HPLC

Sequence

Amino Acid: 1-643

Species

Human

Formulations & Storage [For reference only, actual COA shall prevail!]

Purity

≥90% as determined by SDS-PAGE. ≥95% as determined by SEC-HPLC.

Endotoxin

Please contact us for more information.

Format

Lyophilized

Reconstitution

Allow the vial and reconstitution buffer to equilibrate to room temperature. Briefly centrifuge or tap down the vial to ensure that all lyophilized powder is collected at the bottom of the vial. For the reconstitution of this product, we recommend adding PBS or sterile water to achieve a final antibody concentration of 1 mg/mL. Allow the vial to reconstitute for 10-15 minutes at room temperature with gentle agitation. Avoid vigorous shaking that can cause foaming and antibody denaturation. Aliquot into volumes based on your experiment and store liquid protein at -20°C or -80°C for long time.

Buffer

Lyophilized from sterile

Preservative

None

Storage

Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

More Infomation

Target

Full Name

Erb-B2 Receptor Tyrosine Kinase 3

Research Area

Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778).

May also be activated by CSPG5 (PubMed:15358134).

Involved in the regulation of myeloid cell differentiation (PubMed:27416908).

Biological Process

Cranial nerve development Source: BHF-UCL
Extrinsic apoptotic signaling pathway in absence of ligand Source: BHF-UCL
Heart development Source: BHF-UCL
Negative regulation of cell adhesion Source: BHF-UCL
Negative regulation of neuron apoptotic process Source: BHF-UCL
Negative regulation of secretion Source: BHF-UCL
Negative regulation of signal transduction Source: BHF-UCL
Nervous system development Source: GO_Central
Neuron apoptotic process Source: BHF-UCL
Peripheral nervous system development Source: BHF-UCL
Phosphatidylinositol 3-kinase signaling Source: BHF-UCL
Positive regulation of cell population proliferation Source: GO_Central
Positive regulation of kinase activity Source: GO_Central
Positive regulation of phosphatidylinositol 3-kinase signaling Source: BHF-UCL
Positive regulation of protein tyrosine kinase activity Source: BHF-UCL
Regulation of cell population proliferation Source: BHF-UCL
Schwann cell differentiation Source: BHF-UCL
Signal transduction Source: UniProtKB
Transmembrane receptor protein tyrosine kinase signaling pathway Source: BHF-UCL
Wound healing Source: BHF-UCL

Cellular Location

Isoform 1: Cell membrane
Isoform 2: Secreted

Involvement in disease

Lethal congenital contracture syndrome 2 (LCCS2):
A form of lethal congenital contracture syndrome, an autosomal recessive disorder characterized by degeneration of anterior horn neurons, extreme skeletal muscle atrophy, and congenital non-progressive joint contractures (arthrogryposis). The contractures can involve the upper or lower limbs and/or the vertebral column, leading to various degrees of flexion or extension limitations evident at birth. LCCS2 patients manifest craniofacial/ocular findings, lack of hydrops, multiple pterygia, and fractures, as well as a normal duration of pregnancy and a unique feature of a markedly distended urinary bladder (neurogenic bladder defect). The phenotype suggests a spinal cord neuropathic etiology.
Erythroleukemia, familial (FERLK):
An autosomal dominant myeloproliferative disorder characterized by neoplastic proliferation of erythroblastic and myeloblastic elements with atypical erythroblasts and myeloblasts in the peripheral blood. Disease penetrance is incomplete.

Topology

Extracellular: 20-643
Helical: 644-664
Cytoplasmic: 665-1342

PTM

Autophosphorylated (PubMed:20351256). Ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase (PubMed:20682778).

Tchekmedyian, V., Dunn, L., Sherman, E., Baxi, S. S., Grewal, R. K., Larson, S. M., ... & Ho, A. L. (2022). Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with Vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial. Thyroid, 32(3), 273-282.

De Bacco, F., Orzan, F., Erriquez, J., Casanova, E., Barault, L., Albano, R., ... & Boccaccio, C. (2021). ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma. Cell Reports, 36(4), 109455.

Ngan, H. L., Liu, Y., Fong, A. Y., Poon, P. H. Y., Yeung, C. K., Chan, S. S. M., ... & Lui, V. W. Y. (2020). MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling. Life science alliance, 3(6).

Kiavue, N., Cabel, L., Melaabi, S., Bataillon, G., Callens, C., Lerebours, F., ... & Bidard, F. C. (2020). ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. Oncogene, 39(3), 487-502.

Hafeez, U., Parslow, A. C., Gan, H. K., & Scott, A. M. (2020). New insights into ErbB3 function and therapeutic targeting in cancer. Expert review of anticancer therapy, 20(12), 1057-1074.

Xu, X., Li, L., Li, X., Tao, D., Zhang, P., & Gong, J. (2020). Aptamer-protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells. International Journal of Pharmaceutics, 590, 119963.

Jang, W. J., Jung, S. K., Vo, T. T. L., & Jeong, C. H. (2019). Anticancer activity of paroxetine in human colon cancer cells: Involvement of MET and ERBB3. Journal of Cellular and Molecular Medicine, 23(2), 1106-1115.

Drilon, A., Somwar, R., Mangatt, B. P., Edgren, H., Desmeules, P., Ruusulehto, A., ... & Ganji, G. (2018). Response to ERBB3-Directed Targeted Therapy in NRG1-Rearranged CancersERBB3-Directed Targeted Therapy in NRG1-Rearranged Cancers. Cancer discovery, 8(6), 686-695.

Nguyen, D. Q., Hoang, D. H., Nguyen Vo, T. T., Huynh, V., Ghoda, L., Marcucci, G., & Nguyen, L. X. T. (2018). The role of ErbB3 binding protein 1 in cancer: Friend or foe?. Journal of cellular physiology, 233(12), 9110-9120.

Loree, J. M., Bailey, A. M., Johnson, A. M., Yu, Y., Wu, W., Bristow, C. A., ... & Raghav, K. (2018). Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. JNCI: Journal of the National Cancer Institute, 110(12), 1409-1417.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Human Recombinant ERBB3 protein, ECD, hFc Tag?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Alternative Versions

Cynomolgus, Rhesus Recombinant ERBB3 protein, ECD, Biotin Conjugated, His & AVI Tag (CAT#: V2LY-0526-LY1713)

Cynomolgus, Rhesus Recombinant ERBB3 protein, hFc Tag (CAT#: V2LY-0526-LY1714)

Cynomolgus, Rhesus Recombinant ERBB3 protein, His Tag (CAT#: V2LY-0526-LY1715)

Cynomolgus, Rhesus Recombinant ERBB3 protein (CAT#: V2LY-0526-LY1716)

Human Recombinant ERBB3 protein (CAT#: V2LY-0526-LY4528)

Human Recombinant ERBB3 protein, GST Tag (CAT#: V2LY-0526-LY4529)

Human Recombinant ERBB3 (E928G) protein, GST Tag (CAT#: V2LY-0526-LY4530)

Human Recombinant ERBB3 protein, ECD, Biotin Conjugated, His & AVI Tag (CAT#: V2LY-0526-LY4532)

Human Recombinant ERBB3 protein, ECD, His Tag (CAT#: V2LY-0526-LY4533)

Human Recombinant ERBB3 protein, ECD, His Tag-1 (CAT#: V2LY-0526-LY4534)

Related Products

Mouse Anti-ERBB3 Recombinant Antibody (RT) (CAT#: CBMAB-AP2127LY)

Rabbit Anti-ERBB3 (Phospho-Y1289) Recombinant Antibody (21D3) (CAT#: V2LY-0825-LY622)

Human Recombinant ERBB3 protein, ECD, His Tag-1 (CAT#: V2LY-0526-LY4534)

Human Recombinant ERBB3 protein, GST Tag (CAT#: V2LY-0526-LY4529)

Rabbit Anti-ERBB3 Recombinant Antibody (
6F6) (CAT#: V2LY-0725-LY1496)

Mouse Anti-ERBB3 Recombinant Antibody (CBT4673) (CAT#: V2LY-0625-LY2204)

Cynomolgus, Rhesus Recombinant ERBB3 protein, His Tag (CAT#: V2LY-0526-LY1715)

Rat Recombinant ERBB3 protein, hFc Tag (CAT#: V2LY-0526-LY9420)

Mouse Anti-ERBB3 Recombinant Antibody (CBFYE-1134) (CAT#: CBMAB-E1687-FY)

Mouse Recombinant ERBB3 protein, ECD, hFc Tag (CAT#: V2LY-0526-LY8394)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry